Subklaviyen arteri saran desmoid tümör: Olgu sunumu

Yıl 2023, Cilt: 15 Sayı: 2, 63 - 70, 06.11.2023

Nuray Altındeğer

Öz

Özet
Agresif fibromatozisler (Desmoid Tümör) ilk olarak 1832’de McFarlane tarafından tanımlanmıştır. Miyofibroblastlardan oluşan bir yumuşak doku tümörüdür. Uzak organ metastazı yapmazlar ancak lokal olarak invaziflerdir ve yüksek nüks oranına sahiplerdir. Ekstra-abdominal, abdominal ve intra-abdominal olmak üzere 3 tipi bulunur. Ekstra-abdominal fibromatozisler çocukluk yaş grubunda baskındır. En sık omuz bölgesi olmak üzere uyluk, sırt ve toraks duvarında görülürler. Geniş cerrahi sınırlarla lezyonu çıkarmak zor olduğundan ekstra- abdominal fibromatozislerin nüks oranları yüksektir. Bu çalışmamızda 2. kez nüks etmiş ve subklaviyen arteri çepeçevre sarması nedeniyle artere bypass uygulanan 30 yaşındaki kadın olguyu sunuyoruz.
Abstract
Aggressive fibromatoses (Desmoid Tumor) were first described by McFarlane in 1832. It is a soft tissue tumor composed of myofibroblasts. They do not metastasize to distant organs, but are locally invasive and have a high recurrence rate. There are three types: extra-abdominal, abdominal and intra-abdominal. Extra-abdominal fibromatoses predominate in the childhood age group. They are most commonly seen in the shoulder region, but also in the thigh, back and thoracic wall. Because it is difficult to remove the lesion with wide surgical margins, the recurrence rate of extra-abdominal fibromatosis is high. In this study, we present a 30-year-old female patient who relapsed for the second time and underwent arterial bypass because of surrounding subclavian artery.

Anahtar Kelimeler

desmoid, tümör, arter

Kaynakça

• 1. Micke O, Seegenschmiedt MH. German Cooperative Group on Radiotherapy for Benign Diseases. Radiation therapy for aggressive fibromatosis (desmoid tumors): Results of a national patterns of care study. Int J Radiat Oncol Biol Phys. 2005;61(3):882-891
• 2. Pajares B, Torres E, Jiménez B, et al. Multimodal treatment of desmoid tumours:The significance of local control. Clin Transl Oncol. 2011;13(3):189-193
• 3. Kasper B, Ströbel P, Hohenberger P. Desmoid tumors: Clinical features and treatment options for advanced disease. Oncology. 2011;16(5):682.
• 4. Briand S, Barbier O, Biau D, et al. Wait-and-see policy as a first-line management for extra-abdominal desmoid tumors. JBJS. 2014;96(8):631-638
• 5. Eastley NC, Hennig IM, Esler CP, et al. Nationwide trends in the current management of desmoid (aggressive) fibromatosis. Clin Oncol (R Coll Radiol) 2015;27(6):362–8.
• 6. SK, Phillips RK. Desmoids in familial adenomatous polyposis. Br J Surg 1996;83(11):1494–504
• 7. Eastley N, Aujla R, Silk R, et al. Extra-abdominal desmoid fibromatosis–a sarcoma unit review of practice, long term recurrence rates and survival. Eur J Surg Oncol 2014;40(9):1125–30
• 8. Peng PD, Hyder O, Mavros MN, et al. Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients. Ann Surg Oncol 2012;19(13):4036–42.
• 9. Ballo MT, Zagars GK, Pollack A. Radiation therapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys 1998;42(5):1007–14.
• 10. Kasper B, Baumgarten C, Bonvalot S, et al. Management of sporadic desmoidtype fibromatosis: a European consensus approach based on patients’ and professionals’ expertise - a sarcoma patients EuroNet and European organisation for research and treatment of cancer/soft tissue and bone sarcoma group initiative. Eur J Cancer 2015;51(2):127–36.
• 11. Fiore M, Coppola S, Cannell AJ, et al. Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk. Ann Surg 2014; 259(5):973–8.
• 12. Walker EA, Petscavage JM, Brian PL, et al. Imaging features of superficial and deep fibromatoses in the adult population. Sarcoma 2012;2012: 215810
• 13. Mullen JT, Delaney TF, Kobayashi WK, et al. Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol 2012;19(13): 4028–35
• 14. Coşkun et al. Extra-abdominal desmoid fibromatosis: An evaluation of clinical factors affecting local recurrence rates. Acta Orthop Traumatol Turc 2021; 55(6): 547–551
• 15. Kasper B, Baumgarten C, Garcia J, et al. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Ann Oncol. 2017 Oct;28 (10):2399―408.
• 16. Nieuwenhuis MH, Lefevre JH, Bülow S, et al. Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study. Dis Colon Rectum. 2011 Oct;54(10): 1229―34.
• 17. Huang K, Wang CM, Chen JG, et al. Prognostic factors influencing event-free survival and treatments in desmoid-type fibromatosis: analysis from a large institution. Am J Surg 2014;207(6):847–54.
• 18. Desurmont T, Lefevre JH, Shields C, et al. Desmoid tumour in familial adenomatous polyposis patients: responses to treatments. Fam Cancer 2015;14(1):31–9.
• 19. Desurmont T, Lefevre JH, Shields C, et al. Desmoid tumour in familial adenomatous polyposis patients: responses to treatments. Fam Cancer 2015;14(1):31–9.
• 20. Garbay D, Le Cesne A, Penel N, et al. Chemotherapy in patients with desmoid tumors: a study from the French sarcoma group (FSG). Ann Oncol 2012;23(1): 182–6
• 21. Chugh R, Wathen JK, Patel SR, et al. Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter sarcoma alliance for research through collaboration (SARC) trial. Clin Cancer Res 2010;16(19):4884–91.
• 22. Jo JC, Hong YS, Kim KP, et al. A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis. Invest New Drugs 2014; 32(2):369–76.
• 23. 23.Gounder MM, Lefkowitz RA, Keohan ML, et al. Activity of sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 2011;17(12):4082–90.
• 24. 24.Martin-Liberal J, Benson C, McCarty H, et al. Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis. Clin Sarcoma Res 2013;3(1):13.
• 25. 25. Penel N, Le Cesne A, Bui BN, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French sarcoma group phase II trial with a long-term follow-up. Ann Oncol 2011;22(2):452–7
• 26. Gluck I, Griffith KA, Biermann JS, et al. Role of radiotherapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys 2011;80(3):787–92.
• 27. Grignol et al. Management of Desmoids. Surg Clin N Am 96 (2016) 1015–1030